Fluicell AB (OSTO:FLUI) Other Long-Term Liabilities: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLUI Fluicell AB OSTO:FLUI
58 GF Score
Price kr34.60
GF Value kr33.43
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Other Long-Term Liabilities?

Fluicell AB OSTO:FLUI +8.13% 58 Other Long-Term Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 58/100 and a GF Value™ of kr33.43 (Fairly Valued). The stock has 4 warning signs investors should review.

Fluicell AB's other long-term liabilities for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Fluicell AB's quarterly other long-term liabilities declined from Sep. 2025 (kr0.00 Mil) to Dec. 2025 (kr0.00 Mil) but then increased from Dec. 2025 (kr0.00 Mil) to Mar. 2026 (kr0.00 Mil).

Fluicell AB's annual other long-term liabilities increased from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr0.23 Mil) but then declined from Dec. 2024 (kr0.23 Mil) to Dec. 2025 (kr0.00 Mil).

Fluicell AB Other Long-Term Liabilities Related Terms

Fluicell AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Other Long-Term Liabilities Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.23 0.00

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
OSTO:FLUI
58GF Score
Fluicell AB OSTO:FLUI
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of kr0.00 Mil mean?
Fluicell AB (OSTO:FLUI) has a Other Long-Term Liabilities of kr0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Fluicell AB and its competitors.
Is Fluicell AB's Other Long-Term Liabilities too high?
Fluicell AB's current Other Long-Term Liabilities is kr0.00 Mil. Overall, Fluicell AB has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Other Long-Term Liabilities compare to VRTX and REGN?
Fluicell AB's Other Long-Term Liabilities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Fluicell AB and its competitors. Fluicell AB's current Other Long-Term Liabilities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr33.43, compared to a current price of kr34.60 — trading 3.5% above its estimated fair value. The current Other Long-Term Liabilities is kr0.00 Mil. Fluicell AB's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Other Long-Term Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued. The current stock price of kr34.60 is trading 3.5% above its estimated GF Value™ of kr33.43. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for OSTO:FLUI:

  • Other Long-Term Liabilities: kr0.00 Mil
  • GF Value™: kr33.43 vs. price of kr34.60 (3.5% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
58GF Score

Get the complete analysis for OSTO:FLUI

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.60
Price
kr33.43
GF Value